Inventor · disambiguated record
Elizabeth E. Evans
Also filed as: EVANS ELIZABETH · EVANS ELIZABETH E
17 granted patents·10 pending applications·177 citations·filing 2001–2024
93Inventor score
Files withVACCINEX INC17UNIV ROCHESTER7H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC A FLORIDA NON PROFIT CORPORATION1H LEE MOFFITT CANCER CT & RES1ZAUDERER MAURICE1
Top patents by PatentIndex Score
27 records- 0197US9828435B2Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequencyVACCINEX INC·Filed 2014·Granted Nov 28, 2017·22 cites·19 claims
- 0297US7750125B2Antibodies that bind to the C35 polypeptideUNIV ROCHESTER·Filed 2007·Granted Jul 6, 2010·34 cites·29 claims
- 0396US9243068B2Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastasesVACCINEX INC·Filed 2014·Granted Jan 26, 2016·25 cites·11 claims
- 0495US7563882B2Polynucleotides encoding antibodies that bind to the C35 polypeptideUNIV ROCHESTER·Filed 2003·Granted Jul 21, 2009·43 cites·26 claims
- 0592US8637026B2Anti-C35 antibody combination therapies and methodsZAUDERER MAURICE·Filed 2008·Granted Jan 28, 2014·14 cites·14 claims
- 0690US8790652B2Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesisVACCINEX INC·Filed 2012·Granted Jul 29, 2014·20 cites·22 claims
- 0790US2025032609A1Use of semaphorin-4d antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2024·Application pending·0 cites
- 0889US11078295B2Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2019·Granted Aug 3, 2021·2 cites·20 claims
- 0985US11597765B2Use of semaphorin-4D binding molecules for the treatment of Rett syndromeVACCINEX INC·Filed 2021·Granted Mar 7, 2023·2 cites·16 claims
- 1085US7268207B2Gene differentially expressed in breast and bladder cancer, and encoded polypeptidesUNIV ROCHESTER·Filed 2001·Granted Sep 11, 2007·14 cites·30 claims
- 1179US12070500B2Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasisVACCINEX INC·Filed 2021·Granted Aug 27, 2024·0 cites·13 claims
- 1279US11660330B2Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapyH LEE MOFFITT CANCER CT & RES·Filed 2020·Granted May 30, 2023·1 cites·6 claims
- 1371US10526414B2Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasesVACCINEX INC·Filed 2017·Granted Jan 7, 2020·0 cites·6 claims
- 1470US7968688B2Antibodies that bind to the C35 polypeptideUNIV ROCHESTER·Filed 2009·Granted Jun 28, 2011·0 cites·21 claims
- 1570US7879990B2Polynucleotides encoding antibodies that bind to the C35 polypeptideUNIV ROCHESTER·Filed 2009·Granted Feb 1, 2011·0 cites·26 claims
- 1666US2025052757A1Use of PD-L1 Low Expression Status to Select Subjects for Cancer ImmunotherapyVACCINEX INC·Filed 2024·Application pending·0 cites
- 1765US12201719B2Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapyH LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC A FLORIDA NON PROFIT CORPORATION·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 1865US7910551B2Gene differentially expressed in breast and bladder cancer and encoded polypeptidesUNIV ROCHESTER·Filed 2009·Granted Mar 22, 2011·0 cites·20 claims
- 1961US2023101618A1Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disordersVACCINEX INC·Filed 2022·Application pending·0 cites
- 2060US2023331863A1Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's diseaseVACCINEX INC·Filed 2023·Application pending·0 cites
- 2159US2005158323A1Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cellsVACCINEX INC·Filed 2004·Application pending·0 cites
- 2256US2007081942A1Gene differentially expressed in breast and bladder cancer, and encoded polypeptidesUNIV ROCHESTER·Filed 2006·Application pending·0 cites
- 2354US2008305111A1Anti-C35 antibodies for treating cancerVACCINEX INC·Filed 2007·Application pending·0 cites
- 2453US2009081210A1Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor CellsVACCINEX INC·Filed 2008·Application pending·0 cites
- 2552US2021032322A1Combined inhibition of semaphorin-4d and tgf-beta and compositions thereforVACCINEX INC·Filed 2020·Application pending·0 cites
- 2651US11572408B2Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agentVACCINEX INC·Filed 2018·Granted Feb 7, 2023·0 cites·12 claims
- 2750US2020317788A1Semaphorin-4d antagonists for use in cancer therapyVACCINEX INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elizabeth E. Evans files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →